Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Growth in Short Interest

Monopar Therapeutics Inc. (NASDAQ:MNPR) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 51,300 shares, a growth of 57.8% from the February 13th total of 32,500 shares. Approximately 1.3% of the company’s stock are short sold. Based on an average daily volume of 66,900 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Asset Management L.P. acquired a new stake in Monopar Therapeutics during the 4th quarter worth $3,694,000. Janus Henderson Group PLC purchased a new stake in shares of Monopar Therapeutics in the fourth quarter valued at about $23,435,000. RA Capital Management L.P. purchased a new stake in shares of Monopar Therapeutics in the fourth quarter valued at about $11,247,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Monopar Therapeutics in the fourth quarter valued at about $13,182,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Monopar Therapeutics during the fourth quarter worth about $2,861,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on MNPR shares. HC Wainwright lifted their price objective on shares of Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, January 22nd. Piper Sandler assumed coverage on shares of Monopar Therapeutics in a research report on Friday, January 10th. They issued an “overweight” rating and a $72.00 price objective for the company.

Monopar Therapeutics Price Performance

Shares of MNPR traded up $0.26 during midday trading on Friday, reaching $29.75. The stock had a trading volume of 20,431 shares, compared to its average volume of 361,716. Monopar Therapeutics has a 1-year low of $1.72 and a 1-year high of $54.30. The company’s fifty day simple moving average is $35.77 and its two-hundred day simple moving average is $21.41. The company has a market cap of $181.53 million, a price-to-earnings ratio of -15.10 and a beta of 1.18.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.